Evidence map›Paper›PMID 39760824›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2025

Use of Cardioprotective Adjuncts in Type 1 Diabetes.

Jerry R Greenfield, Ruth Frampton, Kellie Millard, Jennifer R Snaith

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Type 1 diabetes and cardiovascular medicine.Cardiovascular diabetology. Endocrinology reports · 2026
    Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jerry R GreenfieldGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia. j.greenfield@garvan.org.au.
Ruth FramptonGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.
Kellie MillardJDRF Australia, Level 4, 80‑84 Chandos Street, St Leonards, NSW, 2065, Australia.
Jennifer R SnaithGarvan Institute of Medical Research, 384 Victoria St, Darlinghurst, NSW, 2010, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 1 diabetes is associated with excess cardiovascular risk, even after accounting for traditional cardiovascular risk factors, including glycaemia. Hence, there is an urgent need to document the metabolic abnormalities that contribute to the cardiovascular mortality gap in type 1 diabetes, and to examine whether cardioprotective type 2 diabetes medications prevent premature morbidity and mortality in this population.

Indexed as

AdjunctsCardiovascular diseaseGlucagon-like peptide-1 (GLP-1) receptor agonistsInsulin resistanceSodium-glucose cotransporter-2 (SGLT-2) inhibitorsType 1 diabetes

Identifiers

PMID39760824
PMCPMC11794932

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.